Clinical Trial Result Information

Title of Study:
A pilot, open-label, multicentre study evaluating the long-term safety and tolerability of a low-dose peginterferon alfa-2a maintenance monotherapy in chronic hepatitis C patients co-infected with human immunodeficiency virus and who do not respond to a standard regimen of peginterferon alfa-2a plus ribavirin

Fast Facts:

Protocol number:	ML18234
Sponsor:	NV Roche SA
Company division:	Pharmaceutical
Product name:	PEGASYS
Generic name:	peginterferon alfa-2a (40KD)
Phase of development:	III
Therapeutic area, approved indication:	Hepatitis C, Chronic
Date of report:	To be Published

Clinical study summary:
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.

Click here for the protocol registry listing of this trial.